The Technical Analyst
LumiraDx Limited [LMDX]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
LumiraDx Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0160
America/New_York / 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 249.63 mill |
| EPS: | -1.080 |
| P/E: | -0.0100 |
| Earnings Date: | Mar 19, 2024 |
| SharesOutstanding: | 15 602 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2024-01-16 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0100 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0010 - 0.0290 ( +/- 93.33%) |
| ATR Model: 14 days |
Forecast:
01:40 - $-0.0140
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0160 (0.00% ) |
| Volume | 120.55 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LMDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LMDX
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Latest Press Releases
2024-01-05 17:45:00 - Press Release
Lumiradx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9th
London, jan. 05, 2024 (globe newswire) -- lumiradx limited (nasdaq: lmdx)(the “company”) today announced that it has received notification from the nasdaq stock market llc (“nasdaq”) that its securities will be suspended from trading at the open of business on january 9, 2024 as a result of the company's failure to maintain compliance with nasdaq's continued listing standards.
2023-12-29 16:15:00 - Press Release
Lumiradx Announces Agreement To Sell Its cutting Edge Point Of Care Technology Platform To Roche
London, dec. 29, 2023 (globe newswire) -- lumiradx limited (nasdaq: lmdx) (the “company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. the administrators have signed a definitive agreement to sell certain companies of the lumiradx group related to lumiradx's innovative point of care technology to roche.
2023-10-27 16:45:00 - Press Release
Lumiradx Announces Receipt Of Nasdaq Delisting Determination; Plans To Appeal
London, oct. 27, 2023 (globe newswire) -- on october 24, 2023, lumiradx limited (nasdaq: lmdx)(the “company”) received a notice (“notice”) from the listing qualifications department (the “staff”) of the nasdaq stock market llc (“nasdaq”) stating that on april 21, 2023, the staff had notified the company that the bid price of its listed securities had closed at less than $us1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with listing rule 5450(a)(1) (the “minimum bid requirement”). therefore, in accordance with listing rule 5810(c)(3)(a), the company was provided 180 calendar days, or until october 18, 2023, to regain compliance with the minimum bid price requirement...
2023-08-24 07:45:00 - Press Release
Lumiradx Reports Second Quarter 2023 Results
London, aug. 24, 2023 (globe newswire) -- lumiradx limited (nasdaq: lmdx), a next-generation point of care (poc) diagnostics company, today announced financial results for its second quarter ended june 30, 2023.
2023-08-16 16:30:00 - Press Release
Lumiradx To Announce Second Quarter Financial Results And Host Quarterly Conference Call On August 24
London, aug. 16, 2023 (globe newswire) -- lumiradx limited (nasdaq: lmdx), a next-generation point of care (poc) diagnostics company, announced it will release its second quarter financial results on thursday, august 24, 2023. on the day of the release, lumiradx will host a conference call and webcast at 8:30 am eastern time to review the financial results and business highlights.
Latest News
2023-12-29 18:24:36 - Reuters
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
2023-11-30 14:22:03 - PennyStocks
Best Penny Stocks Today? 3 To Watch Under $4 Now
Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares.
2023-11-17 11:19:16 - PennyStocks
Penny Stocks To Buy? 4 Under $5 To Watch Right Now
When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.
2023-10-24 09:11:21 - InvestorPlace
Why Is LumiraDx (LMDX) Stock Down 35% Today?
LumiraDx (NASDAQ: LMDX ) stock is falling on Tuesday as the point-of-care diagnostics company's shares retreat from a rally on Monday. Investors will note that LMDX stock underwent a 217% rally on Monday.
2023-10-20 08:15:02 - Benzinga
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-09-27 11:18:19 - Zacks Investment Research
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-09-21 13:32:38 - Zacks Investment Research
What Makes LumiraDx Limited (LMDX) a New Buy Stock
LumiraDx Limited (LMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-08-16 16:30:00 - GlobeNewsWire
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
2023-06-21 08:38:24 - InvestorPlace
Why Is LumiraDx (LMDX) Stock Up 30% Today?
LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process.
2023-06-20 23:00:34 - PennyStocks
Best Penny Stocks to Buy Under $5? 4 To Watch Now
Penny stocks are shares of companies that trade for less than $5. That's the standard definition of the term, but most traders who're familiar with the idea generally focus on cheaper stocks.